LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients

NAUnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
Dry Eye SyndromesPrimary Sjögren Syndrome
Interventions
DEVICE

LAMELLEYE

Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.

DEVICE

OPTIVE FUSION

Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lamellar Biomedical Ltd

INDUSTRY

collaborator

Robertson Centre for Biostatistics - University of Glasgow

UNKNOWN

collaborator

Glasgow Caledonian University

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER